Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Mirte Muller"'
Autor:
Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D Schouten, Michel M van den Heuvel, Daniela S Thommen, Egbert F Smit, Gerrit A Meijer, Kim Monkhorst
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0293707 (2024)
BackgroundThe efficacy of PD-1 blocking agents in advanced NSCLC has shown prolonged effectiveness, but only in a minority of patients. Multiple biomarkers have been explored to predict treatment benefit, yet their combined performance remains inadeq
Externí odkaz:
https://doaj.org/article/6b18e0bcb87f45658fff43824048aa27
Autor:
Frederik A. van Delft, Milou Schuurbiers, Mirte Muller, Sjaak A. Burgers, Huub H. van Rossum, Maarten J. IJzerman, Hendrik Koffijberg, Michel M. van den Heuvel
Publikováno v:
Heliyon, Vol 8, Iss 10, Pp e10932- (2022)
Serum tumor markers acquired through a blood draw are known to reflect tumor activity. Their non-invasive nature allows for more frequent testing compared to traditional imaging methods used for response evaluations. Our study aims to compare nine pr
Externí odkaz:
https://doaj.org/article/457e2192e21a4b678c80294951df3697
Autor:
Stefano Trebeschi, Zuhir Bodalal, Thierry N. Boellaard, Teresa M. Tareco Bucho, Silvia G. Drago, Ieva Kurilova, Adriana M. Calin-Vainak, Andrea Delli Pizzi, Mirte Muller, Karlijn Hummelink, Koen J. Hartemink, Thi Dan Linh Nguyen-Kim, Egbert F. Smit, Hugo J. W. L. Aerts, Regina G. H. Beets-Tan
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundCheckpoint inhibitors provided sustained clinical benefit to metastatic lung cancer patients. Nonetheless, prognostic markers in metastatic settings are still under research. Imaging offers distinctive advantages, providing whole-body infor
Externí odkaz:
https://doaj.org/article/ffb91a99007c454486ad28fdf5ff1d56
Autor:
Karlijn Hummelink, Mirte Muller, Theodora C. Linders, Vincent van der Noort, Petra M. Nederlof, Paul Baas, Sjaak Burgers, Egbert F. Smit, Gerrit A. Meijer, Michel M. van den Heuvel, Daan van den Broek, Kim Monkhorst
Publikováno v:
ERJ Open Research, Vol 5, Iss 1 (2019)
Objectives Molecular profiling of tumours has become the mainstay of diagnostics for metastasised solid malignancies and guides personalised treatment, especially in nonsmall cell lung cancer (NSCLC). In current practice, it is often challenging to o
Externí odkaz:
https://doaj.org/article/e4ad91cdd5f844d0b347201f793ab091
Autor:
Rianne de Vries, Niloufar Farzan, Timon Fabius, Frans H.C. De Jongh, Patrick M.C. Jak, Eric G. Haarman, Erik Snoey, Johannes C.C.M. In ’T Veen, Yennece W.F. Dagelet, Anke-Hilse Maitland-Van Der Zee, Annelies Lucas, Michel M. Van Den Heuvel, Marguerite Wolf-Lansdorf, Mirte Muller, Paul Baas, Peter J. Sterk
Publikováno v:
Chest.
Autor:
Daniela S. Thommen, Kim Monkhorst, Egbert F. Smit, Gerrit A. Meijer, Ton N. Schumacher, John B.A.G. Haanen, Annegien Broeks, Michel M. van den Heuvel, Alfred Zippelius, Kirsten D. Mertz, Viktor H. Koelzer, Willemijn S.M.E. Theelen, Dennis Peters, Ferry Lalezari, Robert D. Schouten, Mirte Muller, Vincent van der Noort, Karlijn Hummelink
Supplementary Data from PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ea52f853edf2eb4a50b253a02f2ed7a
https://doi.org/10.1158/1078-0432.22488702
https://doi.org/10.1158/1078-0432.22488702
Autor:
Daniela S. Thommen, Kim Monkhorst, Egbert F. Smit, Gerrit A. Meijer, Ton N. Schumacher, John B.A.G. Haanen, Annegien Broeks, Michel M. van den Heuvel, Alfred Zippelius, Kirsten D. Mertz, Viktor H. Koelzer, Willemijn S.M.E. Theelen, Dennis Peters, Ferry Lalezari, Robert D. Schouten, Mirte Muller, Vincent van der Noort, Karlijn Hummelink
Purpose:Durable clinical benefit to PD-1 blockade in non–small cell lung cancer (NSCLC) is currently limited to a small fraction of patients, underlining the need for predictive biomarkers. We recently identified a tumor-reactive tumor-infiltrating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09b470b355e56e5b00cc5a2d7dfae496
https://doi.org/10.1158/1078-0432.c.6532791.v1
https://doi.org/10.1158/1078-0432.c.6532791.v1
Autor:
Daniela S. Thommen, Kim Monkhorst, Egbert F. Smit, Gerrit A. Meijer, Ton N. Schumacher, John B.A.G. Haanen, Annegien Broeks, Michel M. van den Heuvel, Alfred Zippelius, Kirsten D. Mertz, Viktor H. Koelzer, Willemijn S.M.E. Theelen, Dennis Peters, Ferry Lalezari, Robert D. Schouten, Mirte Muller, Vincent van der Noort, Karlijn Hummelink
Supplementary Figure from PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cdeed7c324b99137ac7bc02f4f51cce
https://doi.org/10.1158/1078-0432.22488690
https://doi.org/10.1158/1078-0432.22488690
Autor:
Egbert F. Smit, Joachim G. Aerts, Heinrich Roder, Carlos Oliveira, Joanna Roder, Kim Monkhorst, Anna-Larissa N. Niemeijer, Daan P. Hurkmans, Karlijn Hummelink, Mirte Muller
Purpose:Pretreatment selection of patients with non–small cell lung cancer (NSCLC) who would derive clinical benefit from treatment with immune checkpoint inhibitors (CPIs) would fulfill an unmet clinical need by reducing unnecessary toxicities fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdb5716c144eea6215003dd5cfd9e49b
https://doi.org/10.1158/1078-0432.c.6529436.v1
https://doi.org/10.1158/1078-0432.c.6529436.v1
Autor:
Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D. Schouten, Ferry Lalezari, Dennis Peters, Willemijn S.M.E. Theelen, Viktor H. Koelzer, Kirsten D. Mertz, Alfred Zippelius, Michel M. van den Heuvel, Annegien Broeks, John B.A.G. Haanen, Ton N. Schumacher, Gerrit A. Meijer, Egbert F. Smit, Kim Monkhorst, Daniela S. Thommen
Publikováno v:
Clinical Cancer Research, 28(22), 4893-4906. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 28, 22, pp. 4893-4906
Clinical Cancer Research, 28, 4893-4906
Clinical Cancer Research, 28, 22, pp. 4893-4906
Clinical Cancer Research, 28, 4893-4906
Purpose: Durable clinical benefit to PD-1 blockade in non–small cell lung cancer (NSCLC) is currently limited to a small fraction of patients, underlining the need for predictive biomarkers. We recently identified a tumor-reactive tumor-infiltratin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b20e5d04f85bc26af50bd20f270f7e8
https://doi.org/10.5167/uzh-221928
https://doi.org/10.5167/uzh-221928